Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – February 8, 2023 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Jennifer de los Angeles –	participating in person
Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://zoom.us/webinar/register/WN_73z8ERX7Sv-KeQGP3GVqPg
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 952 7560 1667
Passcode: 69395211

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. December 14, 2022 DUR Board Meeting Minutes
   B. December 14, 2022 DUR Board Recommendations Memorandum
   C. January 11, 2023 DUR Board Recommendations Memorandum

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/Use of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors with Cardiovascular (CV) Benefit in Members with Type 2 Diabetes (T2D) and High CV Risk or Established Atherosclerotic CV Disease (ASCVD) Mailing Update – See Appendix B**
   A. Pharmacy Help Desk Activity for January 2023
   B. Medication Coverage Activity for January 2023
   C. Use of GLP-1 Receptor Agonists and SGLT-2 Inhibitors with CV Benefit in Members with T2D and High CV Risk or Established ASCVD Mailing Update

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

5. **Narrow Therapeutic Index (NTI) List – See Appendix C**
   A. Introduction
   B. NTI List
   C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Update the Approval Criteria for the Antihyperlipidemics – See Appendix D**
   A. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Relyvrio™ (Sodium Phenylbutyrate/Taurursodiol) and Update the Approval Criteria for the Amyotrophic Lateral Sclerosis (ALS) Medications – See Appendix E**
   A. Market News and Updates
   B. Relyvrio™ (Sodium Phenylbutyrate/Taurursodiol) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Update the Approval Criteria for the Gonadotropin-Releasing Hormone (GnRH) Medications – See Appendix F**
   A. Market News and Updates
   B. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

9. **Action Item – Vote to Prior Authorize Vyvgart® (Efgartigimod Alfa-fcab) and Update the Approval Criteria for Empaveli® (Pegcetacoplan), Enspryng® (Satralizumab-mwge), Soliris® (Eculizumab), Ultomiris® (Ravulizumab-cwvz), and Uplizna® (Inebilizumab-cdon) – See Appendix G**
   A. Market News and Updates
   B. Vyvgart® (Efgartigimod Alfa-fcab) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

10. **Action Item – Vote to Prior Authorize Omlonti® (Omidenepag Isopropyl) and Update the Approval Criteria for the Glaucoma Medications – See Appendix H**
    A. Market News and Updates
    B. Omlonti® (Omidenepag Isopropyl) Product Summary
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

11. **Action Item – Vote to Prior Authorize Vabysmo™ (Faricimab-svoa) and Update the Approval Criteria for the Ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitor Medications – See Appendix I**
    A. Market News and Updates
    B. Vabysmo™ (Faricimab-svoa) Product Summary
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

12. **Action Item – Vote to Prior Authorize Auvelity™ (Dextromethorphan/Bupropion) and Venlafaxine 112.5mg Extended-Release (ER) Tablet – See Appendix J**
    A. Market News and Updates
    B. Auvelity™ (Dextromethorphan/Bupropion) Product Summary
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

13. **Action Item – Vote to Prior Authorize Kimmtrak® (Tebentafusp-tebn) and Opdualag™ (Nivolumab/Relatlimab-rmbw) and Update the Approval Criteria for the Skin Cancer Medications – See Appendix K**
    A. Market News and Updates
    B. Kimmtrak® (Tabentafusp-tebn) Product Summary
    C. Opdualag™ (Nivolumab/Relatlimab-rmbw) Product Summary
    D. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

14. **Action Item – Vote to Prior Authorize Lytgobi® (Futibatinib) and Update the Approval Criteria for the Gastrointestinal (GI) Cancer Medications – See Appendix L**
    A. Market News and Updates
    B. Lytgobi® (Futibatinib) Product Summary
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

15. **Action Item – Vote to Prior Authorize Pedmark® (Sodium Thiosulfate) and Vijoice® (Alpelisib) – See Appendix M**
    A. Market News and Updates
    B. Product Summaries
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

16. **Action Item – Vote to Prior Authorize Hyftor™ (Sirolimus Topical Gel) – See Appendix N**
    A. Market News and Updates
    B. Hyftor™ (Sirolimus Topical Gel) Product Summary
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

17. **Action Item – Annual Review of Anti-Migraine Medications – See Appendix O**
    A. Current Prior Authorization Criteria
    B. Utilization of Anti-Migraine Medications
    C. Prior Authorization of Anti-Migraine Medications

D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Anti-Migraine Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

18. Annual Review of Leukemia Medications and 30-Day Notice to Prior Authorize Rezlidhia™ (Olutasidenib) – See Appendix P

A. Current Prior Authorization Criteria
B. Utilization of Leukemia Medications
C. Prior Authorization of Leukemia Medications
D. Market News and Updates
E. Rezlidhia™ (Olutasidenib) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Leukemia Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

19. Annual Review of Anticonvulsants and 30-Day Notice to Prior Authorize Zonisade™ (Zonisamide Oral Suspension) and Ztalmy® (Ganaxolone) – See Appendix Q

A. Current Prior Authorization Criteria
B. Utilization of Anticonvulsants
C. Prior Authorization of Anticonvulsants
D. Market News and Updates
E. Ztalmy® (Ganaloxone) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Anticonvulsants

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

20. Annual Review of Pulmonary Hypertension Medications and 30-Day Notice to Prior Authorize Tadliq® (Tadalafil Oral Suspension) and Tyvaso DPI® (Treprostinil Powder for Inhalation) – See Appendix R

A. Current Prior Authorization Criteria
B. Utilization of Pulmonary Hypertension Medications
C. Prior Authorization of Pulmonary Hypertension Medications
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Pulmonary Hypertension Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

21. Annual Review of Dojolvi® (Triheptanoin) – See Appendix S

A. Current Prior Authorization Criteria
B. Utilization of Dojolvi® (Triheptanoin)
C. Prior Authorization of Dojolvi® (Triheptanoin)
D. Market News and Updates
E. College of Pharmacy Recommendations

F. Utilization Details of Dojolvi® (Triheptanoin)

Items to be presented by Dr. Kottoor, Dr. Muchmore, Chairman:

22. Annual Review of Topical Acne, Psoriasis, and Rosacea Products and 30-Day Notice to Prior Authorize Brimonidine 0.33% Topical Gel (Generic Mirvaso®), Vtama® (Tapinarof), and Zoryve™ (Roflumilast) – See Appendix T

A. Current Prior Authorization Criteria
B. Utilization of Topical Acne, Psoriasis, and Rosacea Products
C. Prior Authorization of Topical Acne, Psoriasis, and Rosacea Products
D. Market News and Updates
E. Product Summaries
F. College of Pharmacy Recommendations
G. Utilization Details of Topical Acne, Psoriasis, and Rosacea Products

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

23. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix U

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

24. Future Business* (Upcoming Product and Class Reviews)

A. Granulocyte Colony-Stimulating Factors (G-CSFs)
B. Growth Hormone Products
C. Lymphoma Medications
D. Multiple Sclerosis (MS) Medications

*Future product and class reviews subject to change.

25. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.